Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Item 3.01. Standard; Transfer of Listing.

As previously disclosed, on October 26, 2022, Statera Biopharma, Inc. (the "Company") received a determination from a Nasdaq Hearings Panel (the "Panel") granting the Company's request for the continued listing of its common stock on The Nasdaq Capital Market ("Nasdaq"), subject to the Company's satisfaction of certain interim milestones and, ultimately, the Company's compliance with all applicable criteria for continued listing on Nasdaq, including the $1.00 bid price and $2.5 million stockholders' equity requirements as set forth in Nasdaq Listing Rules 5550(a)(1) and 5550(b)(2), respectively, by no later than January 31, 2023. On January 10, 2023, the Company received notice from Nasdaq that the Company's was being delisted and that suspension of trading in the Company's common stock will be effective at the open of business on January 12, 2023. The Company intends to appeal the delisting and request a review of the Panel's decision by the Nasdaq Listing and Hearing Review Council.

Effective January 12, 2023, the Company's common stock is quoted on OTC Pink Open Market under the symbol "STAB". In addition, the Company has submitted an application for trading of its common stock on the OTCQB Venture Market (the "OTCQB"). There can be no assurance that the Company's application to trade on the OTCQB will be approved on a timely basis or at all or that the Company will be able to satisfy reporting and other applicable requirements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are filed with this Form 8-K:

Exhibit


   No.       Description of Exhibits
104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).

© Edgar Online, source Glimpses